EntryPoint Capital LLC Makes New Investment in Pulmonx Co. (NASDAQ:LUNG)

EntryPoint Capital LLC bought a new position in shares of Pulmonx Co. (NASDAQ:LUNG) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 11,013 shares of the company’s stock, valued at approximately $102,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LUNG. Primecap Management Co. CA grew its holdings in Pulmonx by 2.2% during the 4th quarter. Primecap Management Co. CA now owns 5,646,451 shares of the company’s stock worth $71,992,000 after acquiring an additional 124,050 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Pulmonx by 6.4% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 989,423 shares of the company’s stock worth $9,172,000 after acquiring an additional 59,835 shares in the last quarter. Campbell & CO Investment Adviser LLC grew its holdings in Pulmonx by 88.8% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 85,672 shares of the company’s stock worth $1,092,000 after acquiring an additional 40,292 shares in the last quarter. Rhenman & Partners Asset Management AB bought a new position in Pulmonx during the 4th quarter worth about $319,000. Finally, Vanguard Group Inc. grew its holdings in Pulmonx by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,023,836 shares of the company’s stock worth $20,906,000 after acquiring an additional 19,364 shares in the last quarter. 91.04% of the stock is currently owned by institutional investors.

Pulmonx Price Performance

Shares of Pulmonx stock opened at $7.75 on Friday. The company has a quick ratio of 6.14, a current ratio of 6.95 and a debt-to-equity ratio of 0.29. The company has a 50 day moving average price of $7.09 and a 200 day moving average price of $9.27. Pulmonx Co. has a 52 week low of $5.67 and a 52 week high of $14.84.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, May 1st. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. Pulmonx had a negative net margin of 80.46% and a negative return on equity of 48.09%. The firm had revenue of $18.85 million during the quarter, compared to analyst estimates of $17.54 million. During the same period last year, the firm posted ($0.42) EPS. As a group, equities research analysts predict that Pulmonx Co. will post -1.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Piper Sandler restated an “overweight” rating and issued a $17.00 price target on shares of Pulmonx in a report on Wednesday, April 3rd. Canaccord Genuity Group lowered their price target on shares of Pulmonx from $16.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, May 2nd. Finally, Lake Street Capital assumed coverage on shares of Pulmonx in a report on Tuesday, June 4th. They issued a “buy” rating and a $12.00 price target on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $15.71.

Insiders Place Their Bets

In other Pulmonx news, insider Geoffrey Beran Rose sold 4,297 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $6.97, for a total transaction of $29,950.09. Following the completion of the transaction, the insider now directly owns 301,203 shares of the company’s stock, valued at approximately $2,099,384.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Pulmonx news, insider Geoffrey Beran Rose sold 4,297 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $6.97, for a total transaction of $29,950.09. Following the completion of the transaction, the insider now directly owns 301,203 shares of the company’s stock, valued at approximately $2,099,384.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel David Aaron Lehman sold 5,475 shares of Pulmonx stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $6.97, for a total transaction of $38,160.75. Following the transaction, the general counsel now directly owns 209,113 shares of the company’s stock, valued at $1,457,517.61. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,140 shares of company stock valued at $85,717. 5.70% of the stock is owned by insiders.

Pulmonx Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.